These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 6531513

  • 1. [Primary pulmonary arterial hypertension. Effects of vasodilators apropos of a case with a pulmonary biopsy].
    Lemoigne F, Bonnaud F, Clary C, Macone F, Blaive B.
    Rev Mal Respir; 1984; 1(6):337-42. PubMed ID: 6531513
    [Abstract] [Full Text] [Related]

  • 2. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
    Saji T, Ozawa Y, Nakayama T, Matsuura H, Hashiguchi R, Matsuo N, Muto H, Yamazaki J, Morishita T, Saito T.
    J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
    [Abstract] [Full Text] [Related]

  • 3. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.
    Menon N, McAlpine L, Peacock AJ, Madhok R.
    Arthritis Rheum; 1998 Mar; 41(3):466-9. PubMed ID: 9506575
    [Abstract] [Full Text] [Related]

  • 4. Modulating the pulmonary circulation: an update.
    Dembinski R, Henzler D, Rossaint R.
    Minerva Anestesiol; 2004 Apr; 70(4):239-43. PubMed ID: 15173703
    [Abstract] [Full Text] [Related]

  • 5. The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use.
    Krasuski RA, Wang A, Harrison JK, Tapson VF, Bashore TM.
    Am Heart J; 2005 Oct; 150(4):725-8. PubMed ID: 16209974
    [Abstract] [Full Text] [Related]

  • 6. [Primary pulmonary hypertension. An overview with special reference to risk-benefit analysis of therapy].
    Schilling W.
    Z Erkr Atmungsorgane; 1991 Oct; 177(3):117-34. PubMed ID: 1808861
    [Abstract] [Full Text] [Related]

  • 7. Unpredictable response to vasodilator therapy in primary pulmonary hypertension.
    Schmiedt MI, Shettigar UR, Siddique M, Barbier G, Bialow M, Carranza S.
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):435-40. PubMed ID: 9726697
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.
    Circulation; 2003 Oct 28; 108(17):2066-9. PubMed ID: 14568893
    [Abstract] [Full Text] [Related]

  • 9. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.
    Gough MS, White RJ.
    Liver Transpl; 2009 Jan 28; 15(1):30-6. PubMed ID: 19109844
    [Abstract] [Full Text] [Related]

  • 10. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N, Lundin S, Ricksten SE.
    J Heart Lung Transplant; 1995 Jan 28; 14(3):436-43. PubMed ID: 7654728
    [Abstract] [Full Text] [Related]

  • 11. Acute hemodynamic effects of nicorandil in patients with primary pulmonary arterial hypertension.
    Yadav R, Anandaraja S, Bhargava B, Jindal R, Goswami KC.
    Indian Heart J; 2005 Jan 28; 57(6):666-9. PubMed ID: 16521635
    [Abstract] [Full Text] [Related]

  • 12. [Therapy of primary pulmonary arterial hypertension: current status].
    Solèr M.
    Schweiz Med Wochenschr; 1994 Oct 01; 124(39):1701-7. PubMed ID: 7939536
    [Abstract] [Full Text] [Related]

  • 13. Sildenafil for primary and secondary pulmonary hypertension.
    Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H.
    Clin Pharmacol Ther; 2002 May 01; 71(5):398-402. PubMed ID: 12011826
    [Abstract] [Full Text] [Related]

  • 14. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
    Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN.
    Circulation; 2003 Sep 09; 108 Suppl 1():II167-73. PubMed ID: 12970227
    [Abstract] [Full Text] [Related]

  • 15. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
    Madden BP, Sheth A, Wilde M, Ong YE.
    Vascul Pharmacol; 2007 Sep 09; 47(2-3):184-8. PubMed ID: 17627899
    [Abstract] [Full Text] [Related]

  • 16. [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
    Yamazaki Y, Matsumoto H, Takeda A, Takahashi T, Sasaki N, Takahashi M, Tsuji T, Fujikane T, Shimizu T.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Aug 09; 35(8):847-53. PubMed ID: 9366158
    [Abstract] [Full Text] [Related]

  • 17. Treatment of pulmonary hypertension with selective pulmonary vasodilators.
    Haj RM, Cinco JE, Mazer CD.
    Curr Opin Anaesthesiol; 2006 Feb 09; 19(1):88-95. PubMed ID: 16547439
    [Abstract] [Full Text] [Related]

  • 18. Oral sildenafil reduces pulmonary hypertension after cardiac surgery.
    Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM.
    Ann Thorac Surg; 2005 Jan 09; 79(1):194-7; discussion 194-7. PubMed ID: 15620942
    [Abstract] [Full Text] [Related]

  • 19. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension.
    Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ.
    Respiration; 2008 Jan 09; 76(2):154-9. PubMed ID: 17804899
    [Abstract] [Full Text] [Related]

  • 20. [Methods for studying vasodilators in man].
    Simon A, Gaillot J.
    J Pharmacol; 1986 Jan 09; 17 Suppl 1():34-40. PubMed ID: 3747538
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.